Shirvan Mitchell 4

What Happened

• Shirvan Mitchell, Silexion Therapeutics Corp (SLXN) Chief Scientific Officer and Chief Development Officer, reported a sale of 22,818 ordinary shares on March 26, 2026. The shares were sold at $1.36 per share for proceeds of approximately $31,032. The reported sale was a "sale-to-cover" transaction to satisfy tax withholding obligations arising from a previously reported grant of fully vested restricted share units (RSUs).

Key Details

• Transaction date and price: 2026-03-26, 22,818 shares at $1.36 per share (total ≈ $31,032).
• Transaction code: S (sale); footnote F1 clarifies this was a sale-to-cover to cover taxes from an RSU grant dated Feb 20, 2026 (reported on Form 4 filed Feb 23, 2026).
• Footnote F2: one row in the filing is informational only (no transaction effected for that row).
• Footnote F3: option/share figures in the filing were adjusted to reflect prior reverse splits (1-for-9 on Nov 29, 2024 and 1-for-15 on Jul 29, 2025).
• Filing: Form 4 filed 2026-03-30 reporting a 2026-03-26 transaction — this filing date is later than the typical two-business-day Form 4 deadline, so the filing appears delayed based on the information provided.
• Shares owned after the transaction: not specified in the transaction details you provided.

Context

• This was a routine tax-withholding sale (sale-to-cover) tied to a fully vested RSU grant rather than an independent open-market sell for investment reasons; such transactions are common when insiders receive equity awards. The filing notes prior reverse splits that affected option/share counts but those adjustments do not change the nature of this tax-withholding sale.